Immunohistochemical Expression of ROS1 in invasive ductal carcinoma of breast in association with hormonal receptor status and Her2Neu expression
DOI:
https://doi.org/10.51985/JBUMDC2024354Keywords:
Invasive breast carcinoma, ROS1, Estrogen receptor, Progesterone receptor, HER2Abstract
Objective: To determine the frequency of immunohistochemical expression of ROS1 in invasive ductal carcinoma of the breast in relation to hormonal receptor status and HER2 expression.
Study Design and Setting: Descriptive cross-sectional study. Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi from May 2022 to Dec 2022.
Methodology: This study was conducted on a sample size comprising 137 patients diagnosed with invasive breast carcinoma (ductal carcinoma) on histopathological biopsy specimen. Immunohistochemistry was performed using ROS1, estrogen receptor, progesterone receptor and HER2 antibodies on patients’ tissue samples. Results were interpreted by two independent histopathologists. Finally data was analyzed using SPSS version 25.
Results: The mean age of sample population was 50.85 ± 12.17 years. 131 patients were women and 6 were men. ROS1 was positive in 54 cases. ROS1 shows weak staining in 41 cases and moderate to strong staining in 13 cases. ER and PR showed no significant statistical correlation with ROS1 expression. HER2 was positive in 37 cases, equivocal in 11 cases and negative in 89 cases. A significant statistical correlation was seen between ROS1 and HER2 as 23 of HER2 positive cases showed ROS1 expression (p=<0.001).
Conclusion: Significant number of ROS1 expressing cases in invasive breast carcinoma can be more revealing in the understanding of pathogenesis of breast carcinoma. In addition, it can also lead to use of certain recent tyrosine kinase inhibitors for treatment of this most common carcinoma in females.
References
Breast cancer. Who.int. [cited 2024 Jul 2]. Available from:
https://www.who.int/news-room/fact-sheets/detail/breastcancer
Khan NH, Duan S-F, Wu D-D, Ji X-Y. Better reporting and
awareness campaigns needed for breast cancer in Pakistani
women. Cancer Manag Res. 2021;13:2125–9. http://dx.doi.org
/10.2147/cmar.s270671
Invasive ductal carcinoma (IDC): Grade, symptoms & diagnosis. Breastcancer.org. [cited 2024 Jul 2]. https://www
.breastcancer.org/types/invasive-ductal-carcinoma
Lin JJ, Shaw AT. Recent Advances in Targeting ROS1 in
Lung Cancer. J Thorac Oncol. 2017;12(11):1611- 1625. doi:
1016/j.jtho.2017.08.002
Davies KD, Doebele RC. Molecular pathways: ROS1 fusion
proteins in cancer. Clin Cancer Res. 2013;19(15):4040–5.
http://dx.doi.org/10.1158/1078-0432.ccr-12-2851
Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi
GR, Arensmeyer KE, et al. New targets in lung cancer. Curr
Oncol Rep. 2020;22(5). Available from: http://dx.doi.org/
1007/s11912-020-00909-8
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano
S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat
Med. 2012;18(3):378–81. Available from: http://dx.doi.org/
1038/nm.2658
Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu T-L,
et al. Analysis of receptor tyrosine kinase ROS1-positive
tumors in non–small cell lung cancer: Identification of a FIGROS1 fusion. Clin Cancer Res. 2012;18(16):4449–57. Available from: http://dx.doi.org/10.1158/1078-0432.ccr-11-3351
Fielder T, Butler J, Tierney G, Holmes M, Lam KY, Satgunaseelan L, et al. ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical
expression of ROS1. Pathology 2022;54(4):399–403. Available
from: dx.doi.org/ 10.1016/ j.pathol.2021.07.012
Huang RSP, Smith D, Le CH, Liu W-W, Ordinario E, Manohar
C, et al. Correlation of ROS1 immunohistochemistry with
ROS1 fusion status determined by fluorescence in situ hybridization. Arch Pathol Lab Med. 2020;144(6):735–41. Available
from: dx.doi.org/10.5858/arpa.2019-0085-oa
Schlam I, Swain SM. HER2-positive breast cancer and tyrosine
kinase inhibitors: the time is now. NPJ Breast Cancer.
;7(1). Available from: http://dx.doi.org/10.1038/s41523-
-00265-1
Andrechek ER, Muller WJ. Tyrosine kinase signalling in
breast cancer: Tyrosine kinase-mediated signal transduction
in transgenic mouse models of human breast cancer. Breast
Cancer Res. 2000;2(3). Available from: http://dx.doi.org
/10.1186/bcr56
Researchgate.net. [cited 2024 Jul 2]. Available from: https://www.researchgate.net/profile / Ameer-Hameedi / publication / 348729528_Immunohistochemical_ Expression_
Of_ROS- 1 _In_ Mammary_ Ductal Carcinoma_ In_ Correlation_ With _Hormonal_ Receptor_ Status_ And_ Her2Neu_
Expression / links / 600d2d6045851553a067a698 / Immunohistochemical – Expression – Of - ROS-1 – In - Mammary
– Ductal - Carcinoma – In – Correlation - With – Hormonal
– Receptor – Status – And - Her2Neu - Expression.pdf
Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Cap.org.
[cited 2024 Jul 2].
Facchinetti F, Friboulet L. Profile of entrectinib and its
potential in the treatment of ROS1-positive NSCLC: evidence
to date. Lung Cancer (Auckl). 2019;10:87–94. Available from:
http://dx.doi.org/10.2147/lctt.s190786
Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase
gene rearrangements in epithelial malignancies. Nat Rev
Cancer. 2013;13(11):772–87. Available from: http://dx.doi.org
/10.1038/nrc3612
Pal P, Khan Z. ROS1-1. J Clin Pathol. 2017;70(12):1001–9.
Available from: http://dx.doi.org/10.1136/jclinpath-2016-
Yoshida A, Tsuta K, Wakai S, Arai Y, Asamura H, Shibata T,
et al. Immunohistochemical detection of ROS1 is useful for
identifying ROS1 rearrangements in lung cancers. Mod Pathol.
;27(5):711–20. Available from: http://dx.doi.org/10.1038/
modpathol.2013.192
Viale G. The current state of breast cancer classification. Ann
Oncol. 2012;23:x207–10. Available from: http://dx.doi.org/10
.1093/annonc/mds326
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann
B, Senn H-J. Strategies for subtypes—dealing with the diversity
of breast cancer: highlights of the St Gallen International
Expert Consensus on the Primary Therapy of Early Breast
Cancer 2011. Ann Oncol. 2011;22(8):1736–47. Available
from: http://dx.doi.org/10.1093/annonc/mdr304
Eom M, Lkhagvadorj S, Oh SS, Han A, Park KH. ROS1
expression in invasive ductal carcinoma of the breast related
to proliferation activity. Yonsei Med J. 2013;54(3):650.
Available from: http://dx.doi.org/10.3349/ymj.2013.54.3.650
Raut A, Yeap I, Mylchreest L, Mills J, Watson N, Gill AJ.
ROS1 immunohistochemistry is not a worthwhile screening
test in breast carcinoma. Pathology. 2015;47:S106. Available
from: http://dx.doi.org/10.1097/01. pat.0000461629.05041.4e
Li K, Liao N, Chen B, Zhang G, Wang Y, Guo L, et al. Genetic
mutation profile of Chinese HER2-positive breast cancers
and genetic predictors of responses to Neoadjuvant anti-HER2
therapy. Breast Cancer Res Treat. 2020;183(2):321–32. Available from: http://dx.doi.org/10.1007/s10549-020-05778-0
Eggemann H, Ignatov T, Burger E, Kantelhardt EJ, Fettke F,
Thomssen C, et al. Moderate HER2 expression as a prognostic
factor in hormone receptor positive breast cancer. Endocr
Relat Cancer. 2015;22(5):725–33. Available from: http://dx.doi.org/10.1530/erc-15-0335
Force J, Sokol ES, Taylor ML, Huang D, Marcom PK, Davare
M, et al. Abstract P3-06-09: Incidence of ROS1 genomic
alterations in breast cancer. Cancer Res. 2020;80 (4_ Supplement): P3-06-09-P3-06–9. Available from: http://dx.doi.
org/10.1158/1538-7445.sabcs19-p3-06-09
O’Neil SR, Weber GA, Deming DA, Burkard ME, Kenny
PA, Richmond CS, et al. Exceptional response to crizotinib
with subsequent response to cabozantinib in metastatic, ROS1-
GOPC fusion–mutated breast cancer. JCO Precis Oncol.
;(7). Available from: http://dx.doi.org /10.1200/po.23.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Muhammad Umair, Ahmed Ahson Khan, Nighat Jamal, Akhter Ali Bajwa, Tabish Hassan, Muhammad Umair Khan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
